PDS Biotechnology Corporation (PDSB)
Develops immunotherapy drugs that train the immune system to fight various cancers.
$0.69-0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-36.6%
The outlook
PDSB trades near the low end of its 52-week range and sits below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage leans bullish on fundamentals, with the average price target implying substantial upside versus the current price. The overall sentiment remains cautious, reflecting tension between the depressed valuation and current market positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range18% of the way from its 52-week low to high
Price targetAvg target +986% vs current price
Analyst price target
~12-month · 3 analysts$7.50average target+986.0% vs now
Now $0.69
Low $3.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$38.6M
52-wk high
$1.55
52-wk low
$0.51
50-day avg
$0.95
200-day avg
$0.89
Trailing P/E
—